Strategic Procurement Regulations: Navigating South Africa’s 2026 Framework for Pharma and Medtech

By João L. Carapinha

May 8, 2026

Strategic Procurement Regulations

South Africa’s Strategic Procurement Regulations, embedded in the Draft General Public Procurement Regulations, 2026, introduce a structured, data-driven framework that fundamentally changes how public institutions acquire goods and services. For pharmaceutical, biotech and medtech companies, the regulations create both opportunities and obligations centred on strategic planning, category management, collaborative contracting vehicles and an expanded range of procurement methods. The rules emphasise value for money across the full lifecycle while requiring institutions to analyse spending, internal needs and market information before developing differentiated sourcing strategies.

Category-Based Sourcing Strategies

Regulation 4 mandates every procuring institution to develop and publish a strategic procurement plan. This plan must categorise goods and services according to their strategic importance and supply-market complexity. Four categories are defined: strategic items of high value or critical to service delivery with limited suppliers; leverage items of high value or critical importance but with many suppliers; bottleneck items of lower value or criticality but with limited supply; and routine or non-critical items that are low-value with abundant suppliers.

Medicines, vaccines and certain reagents frequently fall into the strategic or bottleneck categories because of complex specifications, regulatory requirements and concentrated supplier bases. Capital equipment and high-end diagnostic devices often align with the strategic category, while routine consumables and generic reagents typically sit in the leverage or routine categories. Institutions must tailor sourcing strategies accordingly: long-term collaborative partnerships for strategic categories, demand consolidation and competition for leverage categories, supply-continuity measures for bottleneck categories, and process simplification for routine items.

Framework Agreements and Transversal Contracts

The Strategic Procurement Regulations promote long-term collaborative partnerships, framework agreements and transversal term contracts for recurrent health-product needs. Framework agreements (regulation 15) allow institutions to establish fixed terms with one or more suppliers for a defined period, with call-offs executed either directly or through secondary competition via request-for-quotation. Transversal term contracts (regulation 16) enable treasuries to aggregate demand across organs of state, achieving economies of scale and standardisation for high-volume recurring items such as antiretrovirals, vaccines or laboratory reagents. These vehicles reduce transaction costs and provide predictability for both buyers and suppliers while still permitting competition at the call-off stage when appropriate.

Expanded Procurement Methods and Innovation Pathways

An expanded menu of procurement methods is now available. Open competitive methods include request for quotation (RFQ) for low-value, standardised items below a prescribed threshold; request for bid (RFB) for clear, price-driven procurements above the threshold; and request for proposals (RFP) for complex requirements involving specialised expertise, performance outcomes or innovation. Additional procedures encompass two-stage bidding, competitive dialogue and competitive negotiation for projects whose specifications are not fully defined or that require iterative refinement. Direct procurement (regulation 14) is permitted only in narrow circumstances such as exclusive intellectual-property rights, sole-supplier conditions, national security or international agreements. Electronic bidding, pre-qualification and procurement directly from manufacturers are also provided for under defined conditions.

New provisions address innovation, unsolicited proposals and emergency procurement. Unsolicited bids (regulation 18) may be considered only when the product or service is innovative or offers a demonstrably new and cost-effective method of service delivery and the institution has completed a comprehensive feasibility study. Emergency procurement (regulation 21) allows shortened timeframes, call-offs from existing frameworks or direct procurement when competitive processes are impractical, provided the institution maintains an emergency preparedness plan and publishes a post-emergency report. These mechanisms are particularly relevant during health crises or medicine stock-outs.

International Supply-Chain Obligations

For both local and international suppliers, the regulations impose a clear obligation when procurement occurs overseas: institutions must promote procurement from South African entities and align strategies with host-country laws and applicable trade agreements. International medtech or biotech firms therefore benefit from establishing local partnerships, manufacturing arrangements or distribution agreements that enable South African entities to participate in the supply chain.

Pharmaceutical companies supplying chronic-disease medicines can expect increased use of framework agreements and transversal contracts that reward reliable supply and lifecycle value. Biotech firms offering novel therapies may encounter RFP or competitive-dialogue processes that allow them to propose innovative solutions. Medtech suppliers of capital equipment should prepare for two-stage or competitive-negotiation routes when specifications require customisation or performance guarantees.

Practical Steps for Supplier Readiness

To prepare effectively, companies should take the following steps. First, register promptly on the prospective supplier database and maintain accurate, up-to-date information on ownership, accreditation and capabilities. Second, map their product portfolios against the four procurement categories and develop tailored value propositions that address lifecycle costs, supply security and innovation. Third, build capacity to participate in framework agreements and transversal contracts, including readiness for secondary competition at call-off stage. Fourth, establish internal processes to respond rapidly to RFPs, competitive dialogue and emergency opportunities while ensuring compliance with all bid-validity, security-vetting and contract-management requirements. Fifth, explore partnerships with South African entities to strengthen eligibility for overseas procurement and to support local-content objectives embedded in institutional strategic plans.

These changes reward suppliers that demonstrate strategic alignment, operational reliability and collaborative intent. Companies that invest early in understanding the new planning, category and contracting architecture will be better positioned to secure sustainable public-sector business under the 2026 framework.

Reference url

Recent Posts

Biotechnology Act Europe
Biotechnology Act Europe Driving Innovation and Investment in Life Sciences

By João L. Carapinha

June 18, 2026

The Biotechnology Act Europe offers a once-in-a-generation chance to turn the continent’s world-class life sciences research into scalable commercial successes that remain in Europe rather than migrating elsewhere. By tackling regulatory fragmentation and sharpening investment signals, the legisl...
FDA Importation Program Analysis
FDA Importation Program Analysis on Colorado’s Prescription Drug Initiative

By João L. Carapinha

June 18, 2026

This FDA Importation Program Analysis confirms that Colorado has secured a two-year authorization to import eligible prescription drugs under its Section 804 Importation Program (SIP), demonstrating that significant cost savings for American consumers are achievable without compromising safety or...
real-world evidence Portugal
Enhancing Health Technology Assessment Through Real-World Evidence in Portugal

By João L. Carapinha

June 17, 2026

Real-world evidence Portugal has moved from supplementary tool to statutory requirement under Decree-Law 118/2026, which compels national health systems to share interoperable data so that promised outcomes can be verified after medicines and devices reach patients. The legislation converts one-t...